

PART

*DIVERSIFICATION
OF THE PROTEOME
THROUGH RNA
AND DNA EDITING*

COPYRIGHTED MATERIAL

DIVERSIFYING EXON CODE THROUGH A-TO-I RNA EDITING

*Willemijn M. Gommans
Dylan E. Dupuis
Jill E. McCane
Nicholas E. Tatalias
Stefan Maas*

AN INCREASING number of gene transcripts are found to be subject to recoding by RNA editing. RNA-targeted recoding leads to the substitution of single amino acids in the resulting proteins with subtle or sometimes drastic impact on protein function. New strategies to search for edited genes in mammals have accelerated the discovery of new targets and promise to reveal the many roles of RNA editing in gene regulation.

1.1 INTRODUCTION AND BACKGROUND

According to the central dogma, protein-coding sequences in eukaryotic genomes directly predict the primary structure of the encoded protein. However, processes such as alternative splicing of exons result in the inclusion or omission of protein domains and subdomains and thereby substantially extend the repertoire of expressible protein variants (1). Often, the occurrence and extent of alternative splicing is not predictable from analysis of genomic DNA sequences. Other posttranscriptional RNA modifications also contribute to the complexity of the proteome. One such important mechanism is RNA editing by adenosine modification (2–4), where single adenosine bases are converted into inosine. Since inosine is interpreted by the translation machinery as guanosine (5), A-to-I modification often results in nonsynonymous codon changes leading to protein variants with single amino acid substitutions. To date, it is impossible to predict with reasonable confidence a recoding event in mRNA from analyzing genomic sequence data. In this chapter we are reviewing the current knowledge regarding the prevalence and consequences of A-to-I recoding events in eukaryotic transcripts and discuss recent strategies for identifying and characterizing

recoding editing sites in translated sequences as well as A-to-I editing events in micro RNA transcripts.

1.1.1 Initial Discovery and Context of A-to-I RNA Editing and ADARs

It came as a surprise when in 1991 an A/G discrepancy between genomic and cDNA sequences of the mammalian glutamate-gated ion channel subunit GluR-2 (6) turned out to be due to an adenosine base modification on the RNA level. Editing of this adenosine nucleotide results in the conversion of a glutamine codon into a codon specifying arginine. In fact, this single nucleotide substitution turned out to dominantly regulate ion-permeability in heteromeric receptor molecules and up to today represents maybe the most significant, intriguing, and puzzling case of adenosine modification editing in mammals (see Section 1.2.3).

The initial discovery of adenosine-modification editing quickly led to the identification of several other cases of recoding in nervous-system-specific transcripts, such as additional GluRs (7, 8) and 5HT_{2C}-R (9). In each case a single nucleotide change resulting in an amino acid substitution could be linked to a change in protein function. Since unedited and edited protein variants often are co-expressed in the same cells RNA editing was soon recognized as a potentially important mechanism to diversify genetic information with the ability to enhance the complexity of the eukaryotic transcriptome and proteome.

At the time that the editing event in GluR-2 mRNA was discovered, neither the cellular machinery responsible for this adenosine base substitution nor the molecular mechanism at play was known. The observed A-to-G change in the cloned cDNAs was thought to be a result of either an adenosine modification process that alters this purine into another purine base functionally equivalent to a guanosine, such as hypoxanthine or due to a mechanism that involves removal of the base or of the whole nucleotide followed by introduction of the guanosine.

Interestingly, there was an enzyme known for a long time that converts adenosine mononucleotides to hypoxanthin nucleotides (also termed inosine). This evolutionary conserved adenosine deaminase (ADA) mediates an important step in eukaryotic and prokaryotic nucleotide metabolism. The ADA enzyme is well-studied and has become an important therapeutic target as ADA deficiency leads to various types of immune disorders (10). ADA modifies adenosine mononucleotides employing a hydrolytic deamination mechanism. However, the enzyme is not active on adenosines present in the context of DNA or RNA molecules. In addition to the modification of mononucleotides by ADA, the modification of genomically encoded adenosines to inosines in transfer RNAs (tRNA) has long been known (for reference see 11) and represents a critical feature for the degeneracy of the genetic code (wobble base in the anticodon of several tRNAs). The reaction mechanism and enzyme responsible for generating the wobble base was only recently revealed (12) (see below).

More importantly, a few years before the discovery of adenosine modification editing in pre-mRNAs, a novel enzymatic activity had been discovered that specifically targets adenosines embedded in dsRNA molecules (13, 14). Initially, it was

described as dsRNA unwinding activity, but the actual nature of the molecular process was soon identified as adenosine-to-inosine modifications through an analysis of reaction products (15).

With the establishment of *in vitro* systems for RNA editing based on glutamate receptor transcript minigenes and cellular extracts, the chemical mechanism of the observed A-to-G changes in mRNAs was also soon shown to be the result of A-to-I deamination, catalyzed by a zinc-dependent protein factor (16–18). Furthermore, the cis-acting features in editing targets were characterized, identifying the requirement for partial double-stranded (ds)RNA secondary structures but with no obvious primary sequence signatures (8, 19, 20). This clearly distinguished the A-to-I editing mechanism from the mammalian C-to-U deamination process that involves secondary structure elements in addition to a primary sequence motif (mooring sequence) that guides the RNA modification machinery (see Chapter 11). *In vitro* editing systems also accelerated the isolation and cloning of the first A-to-I RNA editing enzyme from mammals (21–23). It turned out that the responsible protein (initially termed dsRAD, or DRADA, which later was renamed ADAR1) had in fact been investigated by several laboratories as either an interferon-induced protein with potential antiviral functions (24) or as the dsRNA-specific A-to-I editing activity in mammalian cells (see Section 1.1.3) (25, 26). Cloning of the first mammalian ADAR (ADAR1) was followed by the identification of ADAR2 (27) and ADAR3 (28), as well as ADAR homologs in other vertebrates (29, 30), flies (31) and worms (32) (see Section 1.1.3). Also, related enzymes responsible for tRNA-specific A-to-I editing were cloned and characterized in several species (33–35).

The C-to-U editing enzyme (APOBEC1) is remotely sequence-related to the first adenosine-targeting editing enzyme ADAR1, and it is believed that APOBEC1 cytidine deaminase and the deaminase domain of ADARs may share a common ancestor gene (36, 37). Interestingly, neither ADAR1 nor APOBEC1 shows primary sequence homology to adenosine deaminase (ADA), and their predicted (ADAR1) or known (APOBEC1) three-dimensional structures also differ substantially from that of ADA even though the reaction mechanisms catalyzed by ADA, ADAR, and APOBEC1 are highly similar.

1.1.2 Important Cases of Recoding by A-to-I Modification in Pre-mRNA

The first mammalian editing events that were characterized affect several subunits of glutamate-gated ion channels (7, 8) and a prominent serotonin receptor subunit (9). These proteins were all found to be modulated in function by single or multiple site-selective adenosine modifications within their primary transcripts. Serendipity played a central role in the identification of these targets. Only recently, systematic screening methods designed to identify recoding events caused by A-to-I editing have been developed (38–41) leading to the identification of a few additional targets (see Table 1.1).

Overall, the notion that A-to-I RNA recoding editing may be particularly significant for the nervous system is supported by the preponderance of brain tissue-specific editing events. Particularly in the fly (*Drosophila melanogaster*), the

TABLE 1.1 A-to-I Editing in the Coding Regions of Mammalian, Invertebrate and Viral Genes

A. Mammalian Genes					
Function	Gene (Accession Number)	aa Substitution	ADAR ^a	Functional Impact	Ref.
Serotonin receptor	5-HT _{2a} R (NM_000868)	I156V, I156M, N158S, N158D, N158G, I160V	ADAR1 & ADAR2 (B, C and E-site), ADAR1 (A-site), ADAR2 (D-site)	Reduced efficacy G-protein coupling	9
Glutamate receptor	GluR-2 (NM_000826)	R763G Q606R	ADAR1 & ADAR2 ADAR2	Decreased Ca ²⁺ permeability; alteration maturation and cellular trafficking; faster recovery from desensitization	8
Glutamate receptor	GluR-5 (NM_175611)	Q621R	?	Variation in ion permeability	6
Glutamate receptor	GluR-6 (NM_175768)	I567V, Y571C, Q621R	? (Y571C: ADAR2)	Variation in ion permeability	6
Glutamate receptor	GluR-3 (NM_000828)	R775G	ADAR1 & ADAR2	Faster recovery from desensitization	8
Glutamate receptor	GluR-4 (NM_000829)	R765G	ADAR1 & ADAR2	Faster recovery from desensitization	8
Potassium channel	hK _v 1.1 (NM_000217)	I400V	ADAR2	Faster recovery from desensitization	41, 59
Unknown	BC10 (NM_006698)	Y2C, Q5R, K15R	?	? ?	39, 40
Cross-linking actin filaments	FLNA (NM_001456)	Q2333R	?	? ?	40
FMRI interacting protein	CYFIP2 (NM_001037333)	K320E	?	? ?	40
Chloride channel	Gabra-3 (NM_000808)	I342M	ADAR1 & ADAR2	? ?	103
A-to-I editing enzyme	ADAR2 ^b (NM_001033049)	Intronic editing leads to frameshift	ADAR2	Alternative splicing	86

B. Invertebrate and Viral Genes

Function	Gene (Accession number)	Organism	aa Substitution	Functional Impact	Ref.
Potassium channel	SqK _v 1.1 (U50543)	Squid	12 recoding sites	Altered channel kinetics; reduced ability to form tetramers	114
Potassium channel	sq K _v 2 (Y14390)	Squid	12 recoding sites	Altered channel kinetics (channel closure rate & altered slowest time constant)	115
Basic fibroblast growth factor	bFGF (X16627)	<i>Xenopus</i>	Hypermutation	Unknown	116
Editing enzyme	dADAR (AF208535)	<i>Drosophila</i>	S437G	Editing activity	31, 117
Sodium channel	Para (NM_001042816)	<i>Drosophila</i>	Q473R K1455R N1587S	Unknown	118
Glutamate-gated chloride channel	GluRIIE (CG31201)	<i>Drosophila</i>	I27V, K241R, N345S	Unknown	119
Voltage gated calcium channel	cac (NM_206693)	<i>Drosophila</i>	S514G, I815M, N839S, N906S, S937G, M1016V, N1185S, N1368G, N1580D, R1602G	Unknown	120
Amine receptor	DopEcR (CG18314)	<i>Drosophila</i>	I316V Stop323W	Unknown	104
Hydrogen-transporting two-sector ATPase	CG13167	<i>Drosophila</i>	I9V	Unknown	104
Protein phosphatase type 1, regulator	CG9619	<i>Drosophila</i>	S160G	Unknown	104
Transporter activity	Spinster (CG8428)	<i>Drosophila</i>	N67G	Unknown	104

(Continued)

TABLE 1.1 (Continued)

Function	Gene (Accession number)	Organism	aa Substitution	Functional Impact	Ref.
YT521-B	CG12076	<i>Drosophila</i>	Q636R	Unknown	104
Unknown	Tetraspanin 33B (CG14936)	<i>Drosophila</i>	Two silent sites	Unknown	104
Unknown	4f-mp	<i>Drosophila</i>	Hypermutation	Unknown	121
Sodium channel	DSCI (CG9071)	<i>Drosophila</i>	M1174V, I11199V only <i>D. pseudoobscura</i>)	Unknown	41
Potassium channel	Sh (CG12348)	<i>Drosophila</i>	K178E, K178G, K178R, I360M, I464V, T489A, Q49 IR	Unknown	41
Potassium channel	Eag (CG10952)	<i>Drosophila</i>	K467R, Y548C, N567D, K699R	Unknown	41
Potassium channel	Slo (CG10693)	<i>Drosophila</i>	N264D, S977G	Unknown	41
Calcium sensor	Syt (CG3139)	<i>Drosophila</i>	I365V, K377R, I381V, I403M	Unknown	41
SNARE binding	unc-13 (CG2999)	<i>Drosophila</i>	S2371G	Unknown	41
SNARE protein	cpx (CG32490)	<i>Drosophila</i>	I124M, N129D, N129G, N129S	Unknown	41
Unknown	stmB (CG40306)	<i>Drosophila</i>	T1186A	Unknown	41
Adaptor protein	lap (CG2520)	<i>Drosophila</i>	T372A	Unknown	41
nAChR α subunit	D α 5 (CG32975)	<i>Drosophila</i>	I504V, T553A, I554V, I558M	Unknown	41

nAChR subunit	D α 6	<i>Drosophila</i>	N133S, I134V, H138R, N139G, N139S, N139D, I156M, N187S	Unknown	122
nAChR subunit	Amel α 6 (ortholog of D α 6)	<i>Apis mellifera</i>	N164S, K176R, I181M, T184A	Unknown	123
nAChR β subunit	ARD (CG11348)	<i>Drosophila</i>	R56G, I73M	Unknown	41
nAChR β subunit	SBD (CG6798)	<i>Drosophila</i>	T278A	Unknown	41
GABA receptor	Rdl (CG10537)	<i>Drosophila</i>	R122G, I283V, N295G, M360V	Unknown	41
GTPase	Rab26 (GH21984)	<i>Drosophila</i>	K365R	Unknown	38
Ral GTPase activator	Rlip (GH01995)	<i>Drosophila</i>	I229V, E230G, K233E, E254G, K265R	Unknown	38
Rab3 guanyl-nucleotide exchange factor	Rab3-GEF (HL01222)	<i>Drosophila</i>	Q2022R, S2054G	Unknown	
Promotes synaptic vesicle budding	endoA (GH12907)	<i>Drosophila</i>	K129R, K137E	Unknown	38
Synapsin	Syn (CG3985)	<i>Drosophila</i>	R20G	Reduced PKA phosphorylation <i>in vitro</i>	124
AP-2 subunit	α -Adaptin (RH30202)	<i>Drosophila</i>	T207A	Unknown	38
Kinesin-dependent axonal transport	Syd (GH19969)	<i>Drosophila</i>	S983G	Unknown	38

(Continued)

TABLE 1.1 (Continued)

Function	Gene (Accession number)	Organism	aa Substitution	Functional Impact	Ref.
Ca ²⁺ binding protein	Cpn (GH08002)	<i>Drosophila</i>	S402G	Unknown	38
K ⁺ dependent Na ⁺ , Ca ²⁺ antiporter	Nckx30C (HL01989)	<i>Drosophila</i>	K365R	Unknown	38
K ⁺ dependent Na ⁺ , Ca ²⁺ antiporter	CG1090 (GH23040)	<i>Drosophila</i>	S358G	Unknown	38
Na ⁺ , K ⁺ exchanging ATPase	Atpx (GH23483)	<i>Drosophila</i>	Y390C	Unknown	38
Ca ²⁺ binding, acyltransferase activity	CG32699 (HL01250)	<i>Drosophila</i>	I175M	Unknown	38
Trc kinase activator	Mob1 (RH70633)	<i>Drosophila</i>	N91D	Unknown	38
G-protein coupled receptor	Boss (GH10049)	<i>Drosophila</i>	T529A, T533A	Unknown	38
Potassium channel	SK (GHI6664)	<i>Drosophila</i>	Y377C	Unknown	38
Chloride channel	CG31116 (GH23529)	<i>Drosophila</i>	K232R, T259A, K268R, E269G	Unknown	38
Actin nucleation factor	Spir (GH11327)	<i>Drosophila</i>	K339R	Unknown	38
Regulator of actin filament formation	Atx2 (GH01409)	<i>Drosophila</i>	K320R, K337R	Unknown	38
Structural constituent of cytoskeleton	CG32245 (GH04632)	<i>Drosophila</i>	N297D	Unknown	38
ATPase	CG32809 (GH23439)	<i>Drosophila</i>	K179R	Unknown	38
Phosphatidylinositol transporter	Retm (GH05975)	<i>Drosophila</i>	Q245R	Unknown	38
Unknown	CG1552 (GH14443)	<i>Drosophila</i>	K121R	Unknown	38
Unknown	CG31531 (GH25780)	<i>Drosophila</i>	K679E	Unknown	38

Unknown	CG3556 (GHI17087)	<i>Drosophila</i>	I572V	Unknown	38
Unknown	CG9801 (GH23026)	<i>Drosophila</i>	S345G	Unknown	38
Unknown	I(1)G0196 (GH02989)	<i>Drosophila</i>	Q1148R, S1172G, Q1176R	Unknown	38
Unknown	CG12001 (HL01040)	<i>Drosophila</i>	I325V	Unknown	38
Unknown	CG30079 (HL05615)	<i>Drosophila</i>	I127M, T303A, Q343R, Q358R, S360G	Unknown	38
nAChR subunit	α 7-2 (homolog to D α 6 sites)	<i>H. virescens</i>	N133S, N139G, N139S, N139D, I156M	Unknown	122
nAChR subunit	Mdalpha6 (ortholog of D α 6)	<i>Musca domestica</i>	N129S, I130V, H134R, N135S, N135D, N135G, N137S, I152M, N183S Stop196W	Unknown	125
Viral replication	HDAG-p24 (AJ307077)	Hepatitis delta virus		Switch from viral replication to packaging	62

^aPreferential editing enzyme for that target site

^bCauses indirect change in amino acid sequence

large number of neuronal editing targets and the fact that the complete elimination of the A-to-I editing machinery results in a specific neurological phenotype (42) demonstrates a critical role of editing for neural function. However, in mammals, as well as in the fly, the list of non-neuronal recoding targets is steadily growing, though knowledge regarding the physiological significance of recoding editing affecting non-neuronal transcripts is largely lacking.

1.1.2.1 Mammalian Glutamate Receptor Subunits Ionotropic glutamate receptors (iGluRs) constitute an important class of neurotransmitter receptors in the central nervous system that mediate fast excitatory neurotransmission and have been implicated in mechanisms of plasticity, such as learning and memory (43). A total of five glutamate gated ion channel subunits have been shown to be recoded at single positions within their mRNAs affecting a total of eight codons (for recent detailed reviews on the sites and regulatory roles of ion-channel receptor editing, see reference 44 and references therein). Most significantly, the GluR-2 subunit is A-to-I edited at a critical position in the ion channel molecule, which constitutes the molecular determinant for Ca-permeability (6) and in addition regulates channel trafficking (45) and receptor assembly (46). Editing at this position will therefore influence all these processes. The editing event alters a glutamine (Q) codon (CAG) to a codon (CIG) specifying arginine (R). This Q/R site of editing is further remarkable in that virtually 100% of GluR-2 pre-mRNA molecules are edited and therefore almost no GluR-2(Q) protein is present in the brain. The physiological significance of this recoding event became evident when transgenic mice with impaired RNA editing function were engineered. This resulted in mice with a severe epileptic phenotype and premature death (47, 48). It was shown that the reduction in editing at the Q/R site from 100% to ~60% results in a drastically increased conductance and Ca²⁺-influx into principal neurons. These alterations were directly responsible for the observed phenotype, because mice that carry a genomic mutation fixing the RNA editing event in the genome showed a wild-type phenotype despite the editing deficiency (48). Why is the critical arginine codon generated by almost complete editing of the Q/R site and not genomically specified? Currently, it cannot be ruled out that nonedited versions of the GluR-2 subunit have a function during early development or within specific neuronal cell types. However, that function is dispensable for survival and normal development as judged by the lack of a discernable phenotype in transgenic mice that cannot produce nonedited GluR-2 (49). A selective deficiency in GluR-2 Q/R site editing has been implicated in a number of pathological phenotypes in humans (see reference 50 for review), such as amyotrophic lateral sclerosis (ALS). In ALS, the ensuing increase in glutamate receptor Ca²⁺-permeability of affected neurons due to a decreased editing activity may be responsible or a contributing factor to neuronal death (51).

Another editing site changing an arginine (R) codon into a glycine (G) codon is shared between GluR subunits GluR-2, -3, and -4. Here the single amino acid alteration regulates kinetic properties of the heteromeric receptor channel (8) and also modulates receptor biogenesis (52). The extent of editing at the R/G position varies between the different GluR subunits and between neuronal cell types. It also undergoes significant regulation during embryogenesis changing from low level

editing extents during early embryonic stages to high levels in adult individuals (8). The glutamate receptor subunits GluR-5 and -6 are also edited at one or three sites (7), respectively. Here the recoding events modulate the ion-permeability and kinetic properties of the corresponding ion channels (44).

1.1.2.2 Serotonin Receptor Another prominent and well-studied example of A-to-I RNA editing is the serotonin receptor subtype 5-HT_{2C}, which is important for neuronal pathways influencing sensory and motor processes, as well as behaviors. The 5-HT_{2C} receptor is part of a G-protein-coupled transmembrane receptor that couples serotonin neurotransmitter action to intracellular signaling pathways. This mainly leads to the activation of phospholipase C, which, in turn, results in a rise in intracellular inositol phosphates and diacylglycerol. The latter elicits protein kinase activation and induces an increase in intracellular Ca²⁺ concentration. A-to-I RNA editing in 5-HT_{2C} transcripts affects five major sites, which are all located within the same second intracellular loop of the receptor protein (9). Overall, the higher the extent of modification by editing at these sites, the less sensitive the receptor becomes to serotonin activation, which is the result of a decreased G-protein coupling efficiency (53, 54). The 5-HT receptors have been implicated in the etiology of several neurological and behavioral disorders, such as depression, anxiety and schizophrenia. Intriguingly, changes in the RNA editing patterns of 5-HT_{2C} transcripts have been observed in brains of people that suffered from suicidal depression (55). Mice treated with fluoxetine (a serotonin uptake inhibitor) show the converse type of change in the RNA editing pattern of 5-HT_{2C} sequences. These data indicate that the editing extent at these modification sites may be able to change in response to external signals, such as different levels of synaptic serotonin (55). In agreement with these observations, treatment of cells with the cytokine IFN- α resulted in alterations in the editing pattern of 5-HT_{2C} mRNA, which may link the observed depression in patients undergoing cytokine therapy to fluctuations in editing activity (56). Recently, increasing evidence has linked changes in mood and behavior to alterations of serotonin receptor editing (for review see reference 57).

1.1.2.3 Kv1.1 Potassium Channel The mammalian Kv1 subfamily of potassium channels plays an essential role in membrane hyperpolarization during an action potential and in the propagation of action potentials along the plasma membrane (58). The tetrameric receptors form a diverse group of ion channels due to the existence of several subunits and also due to A-to-I RNA modification. Editing of the human Kv1.1 transcripts modulates the kinetics of channel inactivation (59). The editing event in the human Kv1.1 mRNA is related to the site of editing in *Drosophila melanogaster* shaker potassium channels and has independently evolved at the equivalent (analog) site in the *D. melanogaster* Shab potassium channel (59).

This more recently reported editing site in humans stands out because the pre-mRNA that undergoes modification does not contain introns, which means that the partially base-paired RNA fold-back structure is comprised entirely of exonic sequences (41). For each of the cases described above, the molecular determinants for site-selective and efficient editing involve a partially double-stranded RNA fold-back structure in the substrates that is formed between exonic sequences that surround

the to-be-edited adenosine and partially complementary sequence elements in a neighboring intron (see also Section 1.1.3 below).

1.1.2.4 Additional Recoding Targets in Vertebrates, Invertebrates, and Viruses A number of additional recoding events have been reported in mammals (see Table 1.1 and Section 1.1.2), for which there are currently no experimental data available regarding the physiological impact of editing (38–41). Interestingly, they also include non-neuronal transcripts.

In addition, a few examples exist where recoding events are predicted from A/G discrepancies that are only detected in transcripts derived from pathological tissues or cells, such as cancer (prox1, PCNP) and lupus erythematosus (60).

Intriguingly, the hepatitis delta virus (HDV) utilizes the A-to-I editing machinery to regulate viral replication. Within the antigenome of this virus, a site-specific adenosine to inosine modification converts a stop codon into a tryptophan codon (61, 62). This leads to the expression of an HDV antigen variant that suppresses replication and enhances the late stages of the viral life cycle (61). It seems that the viral genome has evolved in a way to utilize the host cell's RNA editing machinery for productive replication.

To date, a total of 77 targets for A-to-I editing have been identified in the fruit fly *D. melanogaster*. Few of these targets, of which the majority are expressed specifically in neurons, have been directly investigated with respect to the consequences of editing for protein function.

1.1.3 Cis-Acting Features for A-to-I Editing

The requirement for a partially double-stranded RNA fold-back structure for editing was first established for the GluR-2 Q/R editing site through meticulous analysis of editing extents in minigene substrates that tested the validity of computer-predicted RNA secondary structures of GluR-2 pre-mRNA transcripts (19). The partially base-paired region in the RNA is formed between sequences flanking the to-be-edited adenosine and a partially complementary sequence [termed the editing site complementary sequence (ECS)], which is often located within a downstream or upstream intron (19, 63, 64). Mutations that weaken the predicted RNA fold surrounding the editing site strongly impair or abolish editing at the Q/R site, whereas other mutations that restore the structure boost the levels of site-selective modification (19). Also, the modified adenosine in the GluR-2 Q/R site structure is in a base-paired configuration and changing the base pair into a mismatch decreases editing efficiency (19). Although this seems to be a rather simple set of parameters determining what constitutes an editing substrate, the analogous analysis of RNA fold-back structures governing editing at other sites revealed that the process is much more complex as in some cases the to-be-edited adenosine may be mismatched (8) or may be part of a loop structure embedded in base-paired regions (64). Based on the available data to date, it is not possible to define structural or sequence requirements that would allow straightforward screening for edited genes in sequence or structure databases (see Section 1.2.2).

Apart from the requirement for a partially base-paired structure, both ADAR1 and ADAR2 show certain nearest-neighbor preferences. The ADAR1 enzyme

preferentially targets adenosines that are preceded by U = A > C > G, and ADAR2 displays a 5'-preference of U = A > C = G as well as a 3'-neighbor preference of U = G > C = A (4, 65). These properties may be related to the reaction mechanism for deamination that is believed to involve a flipping of the adenosine into the enzyme's active site, similar to the mechanism of action employed by DNA methyltransferases (4). Certain sequence environments will make access for the enzyme to the to-be-edited adenosine easier. In summary, there is still an unclear picture with respect to the molecular parameters that determine substrate specificity and editing efficiency in natural recoding targets for A-to-I editing.

1.1.4 Properties of the A-to-I Editing Machinery

The family of mammalian ADAR proteins (ADAR1, ADAR2, and ADAR3) share a common general domain architecture (see Figure 1.1A) mainly comprised of two or three double-stranded RNA binding domains (dsRBDs) and a catalytic adenosine deaminase domain toward the C-terminus (for recent reviews on ADARs see references 66 and 67). Only ADAR1 and ADAR2 have been characterized functionally, whereas ADAR3, although closely sequence related to ADAR2, has not yet been assigned a function and does not display adenosine deaminase activity in established assay systems (28, 68). *In vitro* and in cellular assays, ADAR1 and ADAR2 exhibit site-selective and efficient RNA editing activity apparently without any proteinaceous co-factor requirements (27, 69).




Figure 1.1 Molecular players and mechanism of A-to-I editing. (A) Schematic representation of ADAR domain structures from vertebrates, insects, and nematodes. (B) Depiction of adenosine hydrolytic deamination mechanism with transition state.

Zinc is known to be involved in the catalytic mechanism, where it activates a water molecule that initiates the nucleophilic attack at the C-6 of the targeted adenosine. However, recently it was shown that ADARs are active as dimers (70–73) and also that a small molecule inositol-6-phosphate (IP6) is an essential co-factor for function (74). A crystal structure of the catalytic domain of ADAR2 in conjunction with functional experiments demonstrated that IP6 is critical for protein folding and formation of the catalytic site (74). The mechanism of substrate recognition and site-selectivity of ADARs is not well understood, and ADAR1 and ADAR2 are known to display distinct, but overlapping specificity on known, physiological editing targets. For example, both enzymes seem to be highly active on the glutamate receptor R/G editing sites in GluR-2, -3, and -4. However, the Q/R site of GluR-B, the I/V site of the Kv1.1 potassium channel as well as the D site of the 5-HT_{2C} serotonin receptor are preferentially edited by ADAR2. The enzyme ADAR1 displays preference for the B site of 5-HT_{2C} as well as the amber/W site in the HDV antigenome (27, 56, 75, 76).

One intriguing property of ADARs is that when encountering an extended, perfectly double-stranded RNA molecule, ADARs will promiscuously deaminate up to ~ 50% of all adenosines (77). Further deaminations are probably prevented due to the progressive loss of the substrate's double-strandedness such that the dsRBDs are unable to bind. This highlights that, intrinsically, the ADAR enzymes lack a particular site-selectivity but that most likely the overall three-dimensional shape and sequence environment of edited adenosines in the substrate RNAs provide the specificity seen in physiological recoding targets (4, 78). It has also been suggested that dsRBDs of ADARs may in some cases specifically interact with other structural RNA motifs such as a loop region, thereby mediating site-selective editing (79, 80).

Other organisms, such as insects (31) and nematodes (81), have A-to-I editing machineries in the form of a single ADAR enzyme (i.e., dADAR in *Drosophila melanogaster*) or a single heterodimeric adenosine deaminase targeting mRNAs (*C. elegans* adr-1 and adr-2). They harbor single dsRBDs, and their catalytic domain sequence is closely related to those of vertebrate ADARs. Plants, fungi, and yeast lack ADAR enzymes and RNA-directed adenosine deaminase activity.

Overall, the ADAR enzymes are ubiquitously expressed in most, if not all, cell types (21, 23, 27). An exception is ADAR3, which is detected only in the central nervous system (28). The diversity of ADARs is further enhanced through the expression of alternative splice variants (82–84) and the utilization of alternative promoters (85) and even by A-to-I RNA editing. Mammalian ADAR2 as well as *Drosophila* dADAR edit their own pre-mRNAs (31, 86). In the case of ADAR2, intronic editing creates a novel splice site that leads to expression of a truncated, nonfunctional enzyme (86). In dADAR, site-selective editing alters an amino acid (S-to-G substitution) that was shown to modulate enzymatic activity (31). Alternative promoter usage creates two main ADAR1 transcript variants that differ substantially with respect to subcellular localization and function (87). ADAR1-p110 is expressed from a constitutive promoter and is active primarily within the nucleus (85). Expression of ADAR1-p150 is driven by an interferon inducible promoter and generates an enzyme that harbors a unique N-terminal domain, which conveys specific binding affinity to DNA and RNA in Z-conformation (88) and is actively shuttled between the nucleus and cytoplasm (89). In contrast, both ADAR1-p110 and ADAR2 are

dynamically associated with the nucleolus and might relocate to the nucleoplasm when substrates for editing are expressed (90, 91). Moreover, ADAR2 exists in alternative splice forms that might differ in their RNA editing efficiencies or specificities (83, 84).

1.2 MAIN QUESTIONS IN THE FIELD AND APPROACHES

A critical aspect of understanding the overall impact of A-to-I RNA editing on the regulation of gene expression and for transcriptome and proteome diversity is to delineate all A-to-I editing targets followed by characterization of the functional consequences of editing. Until recently, only a relatively small number of ADAR substrates were known (4) and the A-to-I RNA editing targets seemed to be largely brain-specific. However, the editing machinery was shown to be functionally expressed in many cell types (21, 23, 27), indicating potential additional targets for these enzymes in other tissues. In fact, increasing evidence from biochemical studies further indicated that A-to-I editing occurs in other tissues as well (92) and that overall many more edited genes should exist (see Section 1.2.1).

Previously, ADAR substrates were discovered mainly by coincidence when comparing the cDNA sequence of a cloned gene to their genomic counterparts, in which an adenosine in the genomic sequence appeared as guanosine in the cDNA molecule. In particular, cases with high editing extents, such as the glutamate receptor GluR-2 Q/R site (>99.9% editing), have a higher chance of being detected, also enhanced by the fact that the ensuing amino acid substitution involves a functionally important residue. However, in recent years, several distinct and partially complementary screening methods have been developed to detect novel ADAR substrates.

1.2.1 Biochemical Versus Computational Approaches

The first technique that was developed to systematically screen for RNA molecules that have been modified by the A-to-I editing machinery involves a biochemical procedure to isolate inosine-containing mRNA molecules (93). In this approach, the inosine-containing RNA molecules are chemically modified and then preferentially cleaved at the phosphodiester bond 3' to the inosine nucleotide. The reaction products are subsequently cloned and sequenced followed by analysis of full length cDNAs spanning the identified cleavage sites. This method was successful in that it led to the identification of initially five new cases of A-to-I editing in *C. elegans* mRNAs (94). Interestingly, all detected editing sites were present in the noncoding region of the RNA molecules, and this study therefore gave a first hint that editing might have additional functions besides the alteration of specific codons. In a follow-up study, five additional substrates in *C. elegans* were discovered, as well as 19 novel editing sites in transcripts from human brain (95). Similar to the previous study, all detected editing events were within noncoding regions and the editing of 15 out of the 19 discovered human RNA substrates occurred within transposon derived repeat elements. This finding led to the speculation that repetitive sequences may generally be frequent targets of the editing machinery.

The isolation and cloning of inosine-containing mRNAs using this technique is relatively laborious, and a high background of false positives makes it impractical to use for the comprehensive identification of all editing targets (94, 95).

The recent availability of complete genome sequences and annotations, including the human genome, has made it possible to conduct specific database searches to identify edited genes (see Figure 1.2 for schematic overview of screening methods to identify editing targets). The “smoking gun” of A-to-I RNA editing is an A/G discrepancy between a gene’s cDNA sequence and its genomic counterpart. However, this feature is not sufficient to distinguish genuine RNA editing sites from A/G discrepancies that are the result of a single-nucleotide polymorphism (SNP), a sequencing error in the database, or a mutation introduced during cDNA cloning. Several laboratories embarked on the genome-wide computational screening for A/G discrepancies and through application of statistical methods were able to show that human Alu-type repeat elements present in mRNA sequences are a major target for A-to-I RNA editing (65, 96–98). Alu repeats are approximately 300 bp in length and consist of two monomers linked by an A-rich region. These repeats are highly abundant within the human genome and can occur both in forward and reverse orientation (for review see reference 99). If present within the same mRNA molecule, two oppositely oriented Alu elements can form a partially double-stranded structure generating a substrate for ADAR enzymes. In fact, when validating candidate Alu elements for editing *in vivo*, it turned out that if the two interacting repeat elements are within a few kilobases of one another, the occurrence of editing could always be




Figure 1.2 Screening strategies for identification of recoding targets. Flowchart outlining experimental strategies for delineation of editing events that lead to recoding. Approaches that use biochemical methods for the initial selection of candidate sequences (either through inosine-specific cleavage protocol or affinity chromatography using either ADAR or inosine-specific antibodies) are shown on one side. Approaches that start out by computationally filtering likely editing candidates are indicated on the right. See text for discussion of individual discussions.

confirmed experimentally (65). Between the different studies, several thousand mRNAs with a total of more than 20,000 editing sites were annotated. The main reasons for the only moderate level of overlap between the identified target sets are the different databases used for analysis (for example, either including or excluding EST sequences) and different stringencies when filtering the datasets. Since exonic Alu elements are almost always located within the noncoding regions of an mRNA molecule, it will be intriguing to see if Alu repeat editing may influence the stability, processing, or transport of mRNA molecules. In a few cases it was shown that Alu-mediated editing can destroy or create predicted splice sites (65), which represents another example of how A-to-I editing may regulate gene expression. Because Alu repeat elements are only present in primate genomes, repeat element editing in rodents was shown to occur at a much lower overall rate. This raises the intriguing question of whether editing has a specific role in primate evolution (see Chapter 13 for in-depth review on RNA editing in Alu-type repeats).

Nevertheless, rodent genomes contain other types of repetitive elements, which differ in the sequence composition (100) but which also can give rise to RNA foldback structures and subsequent A-to-I editing. In one case this has been shown to regulate the expression of a mRNA in mouse (101) (see also Chapter 13).

Alu-repeat-mediated editing targets belong to a class of editing substrates that are characterized by low site-selectivity and multiple site modification and are almost all localized in nontranslated sequences of mRNAs or introns. Figure 1.3 depicts the spectrum of currently known targets of A-to-I editing according to site-selectivity of modification, total rate of editing (inosine content), double-strandedness of the RNA fold-back structure, and the prevalence among identified substrates. Recoding targets for editing are located at the very end of the spectrum with the highest site-selectivity, the lowest relative content of inosine per transcript molecule, and the lowest double-strandedness of the substrate RNA.

The many editing events identified in noncoding mRNA sequences and within introns could explain the high amount of inosine that has been detected in mammalian




Figure 1.3 Spectrum of known A-to-I RNA editing targets. The known types of RNA editing targets are shown according to double-strandedness of the RNA fold directing editing, the site-selectivity of the editing event, total inosine content in the message, and the presumed prevalence relative to all known editing targets.

mRNA preparations (92). However, in light of the fact that rodents lack Alu elements, which constitute the main target of the RNA editing machinery in primates, a significant portion of the existing A-to-I editing events may still await discovery. If so, then site-selective targets of recoding may constitute a major fraction of these missing substrates.

Because of the predominance of inosine-containing RNAs that are edited in Alu repeats, experimental approaches to identify other sites of editing are challenging in primates. Ohlson et al. elegantly avoided this problem by using mouse brain tissue samples to selectively screen for ADAR2 specific substrates using affinity chromatography (102). For the detection of novel targets, ADAR2-specific antibodies were used to immunoprecipitate RNA molecules in complex with ADAR2. Reverse transcription and micro-array analysis of these co-precipitated RNA molecules resulted in the detection of up to 200 potential substrates (102), one of which, GABA(A) receptor subunit alpha3, has recently been verified *in vivo* (103).

In another approach to directly detect and isolate inosine-containing RNAs, an antibody was developed that selectively binds to inosine (104). Immunoprecipitated RNA molecules from wild-type and mutant (*ADAR*^{-/-}) flies were reverse transcribed and hybridized to a cDNA array. Comparison between wild-type and *ADAR*^{-/-} cDNA array data led to the identification of 500 putative ADAR target genes (104). In addition, a database search was performed in which *Drosophila* cDNA sequences were compared to their genomic counterparts, as a genomically encoded adenosine will appear as guanosine in the expressed sequence after editing. This resulted in the detection of 800 genes that show an A/G discrepancy within the coding region. Ultimately, by comparing these two groups of putative editing targets, 62 genes were present in both groups. However, editing still has to be proven experimentally for most of these genes (104).

A prerequisite for editing is the presence of a double-stranded RNA structure. This suggests that the sequence surrounding the editing site may be conserved between species to preserve this RNA fold. Indeed, comparative genomics between 18 *Drosophila* species has demonstrated an almost complete absence of mutations in the close vicinity of the exonic edited sites (41). Using this knowledge, Hoopengardner et al. were able to discover 16 novel edited genes in *Drosophila* and one novel site in humans. Several different groups subsequently conducted database searches for finding novel edited human genes, taking into account this conservation between species as well as the established cis-sequence preferences of ADARs (39, 40). This led to the discovery of four novel human genes edited within the coding region.

Moreover, the total of known edited targets in *Drosophila* recently doubled by using *D. melanogaster* genomic and cDNA databases in a computational screen for A-to-G discrepancies, leading to the identification of 27 edited genes (38).

All of the above-described methods have proven to be effective for the discovery of novel edited genes. However, often already known substrates have been missed and there are a high number of false positives detected in each study. The methods for finding novel ADAR substrates still have to be optimized and developed further to allow for the identification of all recoding sites of editing.

1.2.2 Editing of miRNA Sequences

Since double-stranded RNA molecules represent targets not only for ADARs, but also for other dsRNA-binding proteins, such as the components of the RNA silencing pathways, it is not surprising that the natural pathways of RNA editing and RNA silencing are interrelated (reviewed in reference 105). Based on several studies, it has been suggested that there may often be a competition between the editing and silencing machineries for dsRNA molecules. The outcome with respect to the fate of the RNA may largely depend on which set of enzymes engages the RNA first. According to another model, RNA editing may be a nuclear event that can induce silencing on the chromatin level (106). See Chapter 10 for a detailed discussion on the interplay between RNA editing and RNA silencing.

Another related finding has been the discovery that some members of the large family of micro RNA genes are subject to A-to-I RNA editing (see Table 1.2 for list of known edited miRNAs) (107–110). Micro RNAs (miRNAs) constitute a very large and still growing class of RNA molecules, each about 20–22 nt long and may be involved in the regulation of up to one-third of all protein-coding genes through a mechanism of translational repression (111). The analysis of cis-acting preferences of ADAR enzymes and the characterization of RNA secondary structures of known recoding targets raised the question of whether miRNA precursor molecules might also represent ADAR targets. A hallmark feature of all miRNAs is that they are expressed

TABLE 1.2 Validated Edited miRNAs

Origin	miRNA	Edited Positions ^a	Consequence	Reference
Mammalian	miRNA-142	–12, 4, 5, 6, 9, 12, 19, 40, 50, 55, 62	No processing by Drosha-DGCR8; degradation by Tudor-SN	110 ^b
	miRNA-376 cluster	4, 44	Altered target gene silencing	112
	miRNA-22	Human: 58, 62, 71, 80 Mouse: 12, 63, 64	Unknown	107
	miRNA-151	49	Unknown	109 ^c
	miRNA-197	14	Unknown	109 ^c
	miRNA-223	20	Unknown	109 ^c
	miRNA-376a	9, 49	Unknown	109 ^c
	miRNA-379	10	Unknown	109 ^c
	miRNA-99a	13	Unknown	109 ^c
	Kaposi sarcoma- associated virus (KSHV)	miRNA-K12-10	47	Unknown

^aRelative to the 5' end of the mature miRNA.

^bEditing *in vitro* also detected in three other miRNAs.

^cReference reports possible editing of six other miRNA that may be annotated on the wrong genomic strand.

as precursor molecules that form a hairpin structure from which subsequently the mature miRNA is excised (see Figure 1.4). These hairpin structures are reminiscent of known to be RNA fold-back structures that are subject to editing. The pre-miRNA transcripts of miRNAs (termed pri-miRNAs) are usually several hundred nucleotides long and are first processed into an approximately 70 to 90-nt pre-miRNA in the nucleus and then, after export into the cytoplasm, a second processing step generates the mature approximately 20 to 22-nt functional miRNA.

The occurrence of A-to-I RNA editing in a miRNA molecule was first described for human and mouse miRNA22 (107). Although the editing levels in native human and mouse tissues are low, it was shown in cellular assays that ADARs specifically target the same nucleotide positions that are also modified *in vivo*. The observed editing events were located both within and outside of the embedded mature miRNA sequence and predicted that either miRNA maturation or the targeting specificity of the mature miRNA could be affected. The next miRNA that was found to undergo




Figure 1.4 miRNA editing. The central panel outlines the biogenesis pathway for miRNAs with the main steps of pri-miRNA synthesis, pre-miRNA generation through Drosha cleavage, nuclear export (involving the Ran-GTP/Exp5 pathway), and final processing by Dicer in the cytosol. To the left the potential consequence of RNA editing in miRNA precursor sequences outside of the mature miRNA region is indicated. Due to editing, the RNA structure is altered in such a way that Drosha is not able to process the RNA further. This scenario may be involved in the regulation of miRNA 142 (110). To the right, the possible consequence of editing within the mature miRNA sequence is depicted. If ADARs modify the miRNA sequence and processing proceeds, altered, mature miRNA is formed, which may exhibit changed target specificity. An example for such an event is miRNA 376, where the edited miRNA has a very different target spectrum than the nonedited version (112). See text for details.

A-to-I editing was the Kaposi-sarcoma-associated virus miRNA-K12-10b (108). High levels of edited, mature miRNA-K12-10b were observed in host cells; however, also here the functional implications of editing have not been addressed. A first insight into the consequences of A-to-I editing of miRNA precursors was provided by the finding that editing of two sites in miRNA-142 leads to suppression of further maturation and potentially targets edited pri-miRNA-142 transcripts for degradation by Tudor-SN (110). Consequently, in editing-deficient mice, expression of mature miRNA-142 was increased (110).

Another intriguing example of miRNA editing is miRNA-376. In this case, mature edited miRNA-376 could be detected and the editing event has a strong impact on miRNA target predictions (112). It could be shown that a target specific for the edited miRNA-376 sequence was upregulated in ADAR knockout mice (112).

Currently, it is estimated that between 6% and 10% of all miRNA genes are subject to A-to-I modification (109). The identification of editing events in miRNAs demonstrate that miRNA transcripts are subject to post-transcriptional modification and that the functions of miRNAs may not be completely deducible when simply analyzing their genomic sequences. RNA editing increases the diversity of the “miRNome” and should be considered when analyzing miRNA function or when contemplating the use of miRNAs as laboratory tools or for developing therapeutics.

1.3 FUTURE DIRECTIONS: EVOLUTION OF EDITING SITES AND MACHINERY

An unresolved, fundamental question regarding RNA editing is: How do novel editing sites arise in nature? This question is related to the questions of how does an editing site evolve to become more or less prevalent, and how may RNA editing shape the evolution of phenotypes and species?

First of all it is important to consider in what way RNA editing may be beneficial for an organism and how it compares to evolving additional protein subunits or splice variants as a mechanism to generate complexity and diversity. An important insight is the fact that RNA editing often seems to target codons of invariant or highly conserved amino acid residues. This is the result of an at least two-step process, first enabling editing at the novel site and then the process of establishing it permanently and optimizing the level of editing at the site.

Recoding messages on the RNA level to a certain extent enables the organism to produce protein variants that would otherwise not be allowed because DNA-based changes are much more drastic either—or decisions that will immediately fix the change in one allele of the gene. For highly conserved residues, such drastic changes are not permissive and will likely be selected against.

One current model of how generally novel A-to-I RNA editing sites arise involves “continuous probing” of the sequence space for novel sites by nature (36). It is based on the finding that the essential feature for editing is the substrate structure—an RNA fold that directs the ubiquitously expressed editing machinery to a specific adenosine for modification. RNA folding is inherently complex and dynamic,

meaning that various alternative three-dimensional structures exist for a given pre-mRNA sequence, and, importantly, small changes within the primary sequence can lead to drastic changes in outcome. The “continuous probing” model postulates that there is ongoing, low-level background editing at many sites in pre-mRNA, whereas the recoding editing events that have been characterized to date represent the few modification sites whose associated RNA folds have been selected for and evolved to support significant editing levels.

What is currently the evidence that would support this model? And can it be tested experimentally? A critical prerequisite for the continuous probing of RNA structures is that the secondary and tertiary structures of pre-mRNAs be less constraining than, for example, the protein-coding sequences themselves. Since eukaryotic pre-mRNAs usually contain long noncoding introns along with relatively shorter exons, mutations within intronic sequences are often tolerable with no impact on gene expression. Novel RNA structures involving highly conserved exonic sequences and rapidly evolving introns may therefore arise at a high rate.

Intriguingly, it has been experimentally demonstrated that species-specific editing sites within the same exon of the synaptotagmin I gene can be interchanged simply by introducing a few point mutations within distant intronic sequences (113). It is also well known that small changes introduced into an intronic sequence involved in a RNA fold that mediates editing can drastically enhance or impair editing rates and site specificity (19).

Could there be an additional advantage provided to an organism maintaining a low-level background editing throughout the transcriptome? It is possible that the latent ability to edit certain sites could represent a survival advantage for the organism if environmental conditions change. It could then adapt much faster by increasing the production of the edited variant. One way to test the “continuous background editing model” is to try to detect the ongoing low-level of background editing. This will be challenging since the error rate of any detection method to be used will likely be as high as or exceed the background level of editing. Maybe proteomics approaches can give the answer if it becomes possible to specifically detect recoded protein variants. Alternatively, model systems with editable reporter genes may be useful in detecting low-level A-to-I modifications.

If continuous editing occurs, the plasticity of eukaryotic transcripts may be much more pronounced than previously anticipated and could have important consequences on how to approach evolutionary questions of adaptability, variation, and speciation.

REFERENCES

1. Baltimore, D. (2001) Our genome unveiled. *Nature* **409**, 814–816.
2. Maas, S., Rich, A., and Nishikura, K. (2003) A-to-I RNA editing: Recent news and residual mysteries. *J Biol Chem* **278**, 1391–1394.
3. Schaub, M., and Keller, W. (2002) RNA editing by adenosine deaminases generates RNA and protein diversity. *Biochimie* **84**, 791–803.
4. Bass, B. L. (2002) RNA editing by adenosine deaminases that act on RNA. *Annu Rev Biochem* **71**, 817–846.

5. Basilio, C., Wahba, A. J., Lengyel, P., Speyer, J. F., and Ochoa, S. (1962) Synthetic polynucleotides and the amino acid code. *Proc Natl Acad Sci USA* **48**, 613–616.
6. Sommer, B., Kohler, M., Sprengel, R., and Seeburg, P. H. (1991) RNA editing in brain controls a determinant of ion flow in glutamate-gated channels. *Cell* **67**, 11–19.
7. Kohler, M., Burnashev, N., Sakmann, B., and Seeburg, P. H. (1993) Determinants of Ca²⁺ permeability in both TM1 and TM2 of high affinity kainate receptor channels: Diversity by RNA editing. *Neuron* **10**, 491–500.
8. Lomeli, H., Mosbacher, J., Melcher, T., Hoyer, T., Geiger, J. R., Kuner, T., Monyer, H., Higuchi, M., Bach, A., and Seeburg, P. H. (1994) Control of kinetic properties of AMPA receptor channels by nuclear RNA editing. *Science* **266**, 1709–1713.
9. Burns, C. M., Chu, H., Rueter, S. M., Hutchinson, L. K., Canton, H., Sanders-Bush, E., and Emeson, R. B. (1997) Regulation of serotonin-2C receptor G-protein coupling by RNA editing. *Nature* **387**, 303–308.
10. Hershfield, M. S. (1998) Adenosine deaminase deficiency: Clinical expression, molecular basis, and therapy. *Semin Hematol* **35**, 291–298.
11. Grosjean, H., Auxilien, S., Constantinesco, F., Simon, C., Corda, Y., Becker, H. F., Foiret, D., Morin, A., Jin, Y. X., Fournier, M., *et al.* (1996) Enzymatic conversion of adenosine to inosine and to N1-methylinosine in transfer RNAs: a review. *Biochimie* **78**, 488–501.
12. Gerber, A. P., and Keller, W. (1999) An adenosine deaminase that generates inosine at the wobble position of tRNAs. *Science* **286**, 1146–1149.
13. Bass, B. L., and Weintraub, H. (1987) A developmentally regulated activity that unwinds RNA duplexes. *Cell* **48**, 607–613.
14. Wagner, R. W., and Nishikura, K. (1988) Cell cycle expression of RNA duplex unwindase activity in mammalian cells. *Mol Cell Biol* **8**, 770–777.
15. Bass, B. L., and Weintraub, H. (1988) An unwinding activity that covalently modifies its double-stranded RNA substrate. *Cell* **55**, 1089–1098.
16. Melcher, T., Maas, S., Higuchi, M., Keller, W., and Seeburg, P. H. (1995) Editing of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptor GluR-B pre-mRNA *in vitro* reveals site-selective adenosine to inosine conversion. *J Biol Chem* **270**, 8566–8570.
17. Rueter, S. M., Burns, C. M., Coode, S. A., Mookherjee, P., and Emeson, R. B. (1995) Glutamate receptor RNA editing *in vitro* by enzymatic conversion of adenosine to inosine. *Science* **267**, 1491–1494.
18. Yang, J. H., Sklar, P., Axel, R., and Maniatis, T. (1995) Editing of glutamate receptor subunit B pre-mRNA *in vitro* by site-specific deamination of adenosine. *Nature* **374**, 77–81.
19. Higuchi, M., Single, F. N., Kohler, M., Sommer, B., Sprengel, R., and Seeburg, P. H. (1993) RNA editing of AMPA receptor subunit GluR-B: A base-paired intron-exon structure determines position and efficiency. *Cell* **75**, 1361–1370.
20. Casey, J. L., and Gerin, J. L. (1995) Hepatitis D virus RNA editing: specific modification of adenosine in the antigenomic RNA. *J Virol* **69**, 7593–7600.
21. Kim, U., Wang, Y., Sanford, T., Zeng, Y., and Nishikura, K. (1994) Molecular cloning of cDNA for double-stranded RNA adenosine deaminase, a candidate enzyme for nuclear RNA editing. *Proc Natl Acad Sci USA* **91**, 11457–11461.
22. Hurst, S. R., Hough, R. F., Aruscavage, P. J., and Bass, B. L. (1995) Deamination of mammalian glutamate receptor RNA by *Xenopus* dsRNA adenosine deaminase: Similarities to *in vivo* RNA editing. *RNA* **1**, 1051–1060.
23. O'Connell, M. A., Krause, S., Higuchi, M., Hsuan, J. J., Totty, N. F., Jenny, A., and Keller, W. (1995) Cloning of cDNAs encoding mammalian double-stranded RNA-specific adenosine deaminase. *Mol Cell Biol* **15**, 1389–1397.
24. Weier, H. U., George, C. X., Greulich, K. M., and Samuel, C. E. (1995) The interferon-inducible, double-stranded RNA-specific adenosine deaminase gene (DSRAD) maps to human chromosome 1q21.1–21.2. *Genomics* **30**, 372–375.
25. O'Connell, M. A., and Keller, W. (1994) Purification and properties of double-stranded RNA-specific adenosine deaminase from calf thymus. *Proc Natl Acad Sci USA* **91**, 10596–10600.
26. Kim, U., Garner, T. L., Sanford, T., Speicher, D., Murray, J. M., and Nishikura, K. (1994) Purification and characterization of double-stranded RNA adenosine deaminase from bovine nuclear extracts. *J Biol Chem* **269**, 13480–13489.

27. Melcher, T., Maas, S., Herb, A., Sprengel, R., Seeburg, P. H., and Higuchi, M. (1996) A mammalian RNA editing enzyme. *Nature* **379**, 460–464.
28. Melcher, T., Maas, S., Herb, A., Sprengel, R., Higuchi, M., and Seeburg, P. H. (1996) RED2, a brain-specific member of the RNA-specific adenosine deaminase family. *J Biol Chem* **271**, 31795–31798.
29. Slavov, D., Crnogorac-Jurcevic, T., Clark, M., and Gardiner, K. (2000) Comparative analysis of the DRADA A-to-I RNA editing gene from mammals, pufferfish and zebrafish. *Gene* **250**, 53–60.
30. Slavov, D., Clark, M., and Gardiner, K. (2000) Comparative analysis of the RED1 and RED2 A-to-I RNA editing genes from mammals, pufferfish and zebrafish. *Gene* **250**, 41–51.
31. Palladino, M. J., Keegan, L. P., O'Connell, M. A., and Reenan, R. A. (2000) dADAR, a *Drosophila* double-stranded RNA-specific adenosine deaminase is highly developmentally regulated and is itself a target for RNA editing. *RNA* **6**, 1004–1018.
32. Hough, R. F., Lingam, A. T., and Bass, B. L. (1999) *Caenorhabditis elegans* mRNAs that encode a protein similar to ADARs derive from an operon containing six genes. *Nucleic Acids Res* **27**, 3424–3432.
33. Gerber, A., Grosjean, H., Melcher, T., and Keller, W. (1998) Tad1p, a yeast tRNA-specific adenosine deaminase, is related to the mammalian pre-mRNA editing enzymes ADAR1 and ADAR2. *EMBO J* **17**, 4780–4789.
34. Maas, S., Gerber, A. P., and Rich, A. (1999) Identification and characterization of a human tRNA-specific adenosine deaminase related to the ADAR family of pre-mRNA editing enzymes. *Proc Natl Acad Sci USA* **96**, 8895–8900.
35. Maas, S., Kim, Y. G., and Rich, A. (2000) Sequence, genomic organization and functional expression of the murine tRNA-specific adenosine deaminase ADAT1. *Gene* **243**, 59–66.
36. Maas, S., and Rich, A. (2000) Changing genetic information through RNA editing. *Bioessays* **22**, 790–802.
37. Gerber, A. P., and Keller, W. (2001) RNA editing by base deamination: More enzymes, more targets, new mysteries. *Trends Biochem Sci* **26**, 376–384.
38. Stapleton, M., Carlson, J. W., and Celniker, S. E. (2006) RNA editing in *Drosophila melanogaster*: New targets and functional consequences. *RNA* **12**, 1922–1932.
39. Clutterbuck, D. R., Leroy, A., O'Connell, M. A., and Semple, C. A. (2005) A bioinformatic screen for novel A-I RNA editing sites reveals re-coding editing in BC10. *Bioinformatics* **21** (11), 2590–2595.
40. Levanon, E. Y., Hallegger, M., Kinar, Y., Shemesh, R., Djinovic-Carugo, K., Rechavi, G., Jantsch, M. F., and Eisenberg, E. (2005) Evolutionarily conserved human targets of adenosine to inosine RNA editing. *Nucleic Acids Res* **33**, 1162–1168.
41. Hoopengardner, B., Bhalla, T., Staber, C., and Reenan, R. (2003) Nervous system targets of RNA editing identified by comparative genomics. *Science* **301**, 832–836.
42. Palladino, M. J., Keegan, L. P., O'Connell, M. A., and Reenan, R. A. (2000) A-to-I pre-mRNA editing in *Drosophila* is primarily involved in adult nervous system function and integrity. *Cell* **102**, 437–449.
43. Mayer, M. L., and Armstrong, N. (2004) Structure and function of glutamate receptor ion channels. *Annu Rev Physiol* **66**, 161–181.
44. Seeburg, P. H., and Hartner, J. (2003) Regulation of ion channel/neurotransmitter receptor function by RNA editing. *Curr Opin Neurobiol* **13**, 279–283.
45. Greger, I. H., Khatri, L., and Ziff, E. B. (2002) RNA editing at arg607 controls AMPA receptor exit from the endoplasmic reticulum. *Neuron* **34**, 759–772.
46. Greger, I. H., Khatri, L., Kong, X., and Ziff, E. B. (2003) AMPA receptor tetramerization is mediated by Q/R editing. *Neuron* **40**, 763–774.
47. Brusa, R., Zimmermann, F., Koh, D. S., Feldmeyer, D., Gass, P., Seeburg, P. H., and Sprengel, R. (1995) Early-onset epilepsy and postnatal lethality associated with an editing-deficient GluR-B allele in mice. *Science* **270**, 1677–1680.
48. Higuchi, M., Maas, S., Single, F. N., Hartner, J., Rozov, A., Burnashev, N., Feldmeyer, D., Sprengel, R., and Seeburg, P. H. (2000) Point mutation in an AMPA receptor gene rescues lethality in mice deficient in the RNA-editing enzyme ADAR2. *Nature* **406**, 78–81.
49. Kask, K., Zamanillo, D., Rozov, A., Burnashev, N., Sprengel, R., and Seeburg, P. H. (1998) The AMPA receptor subunit GluR-B in its Q/R site-unedited form is not essential for brain development and function. *Proc Natl Acad Sci USA* **95**, 13777–13782.

50. Maas, S., Kawahara, Y., Tamburro, K. M., and Nishikura, K. (2006) A-to-I RNA Editing and Human Disease. *RNA Biol* **3** (1), 1–9.
51. Kawahara, Y., Ito, K., Sun, H., Aizawa, H., Kanazawa, I., and Kwak, S. (2004) Glutamate receptors: RNA editing and death of motor neurons. *Nature* **427**, 801.
52. Greger, I. H., Akamine, P., Khatri, L., and Ziff, E. B. (2006) Developmentally regulated, combinatorial RNA processing modulates AMPA receptor biogenesis. *Neuron* **51**, 85–97.
53. Herrick-Davis, K., Grinde, E., and Niswender, C. M. (1999) Serotonin 5-HT_{2C} receptor RNA editing alters receptor basal activity: Implications for serotonergic signal transduction. *J Neurochem* **73**, 1711–1717.
54. Price, R. D., and Sanders-Bush, E. (2000) RNA editing of the human serotonin 5-HT_{2C} receptor delays agonist-stimulated calcium release. *Mol Pharmacol* **58**, 859–862.
55. Gurevich, I., Tamir, H., Arango, V., Dwork, A. J., Mann, J. J., and Schmauss, C. (2002) Altered editing of serotonin 2C receptor pre-mRNA in the prefrontal cortex of depressed suicide victims. *Neuron* **34**, 349–356.
56. Yang, W., Wang, Q., Kanes, S. J., Murray, J. M., and Nishikura, K. (2004) Altered RNA editing of serotonin 5-HT_{2C} receptor induced by interferon: Implications for depression associated with cytokine therapy. *Brain Res Mol Brain Res* **124**, 70–78.
57. Gardiner, K., and Du, Y. (2006) A-to-I editing of the 5HT_{2C} receptor and behaviour. *Brief Funct Genomic Proteomic* **5**, 37–42.
58. Dolly, J. O., and Parcej, D. N. (1996) Molecular properties of voltage-gated K⁺ channels. *J Bioenerg Biomembr* **28**, 231–253.
59. Bhalla, T., Rosenthal, J. J., Holmgren, M., and Reenan, R. (2004) Control of human potassium channel inactivation by editing of a small mRNA hairpin. *Nat Struct Mol Biol* **11**, 950–956.
60. Laxminarayana, D., Khan, I. U., and Kammer, G. (2002) Transcript mutations of the alpha regulatory subunit of protein kinase A and up-regulation of the RNA-editing gene transcript in lupus T lymphocytes. *Lancet* **360**, 842–849.
61. Polson, A. G., Ley, H. L., 3rd Bass, B. L., and Casey, J. L. (1998) Hepatitis delta virus RNA editing is highly specific for the amber/W site and is suppressed by hepatitis delta antigen. *Mol Cell Biol* **18**, 1919–1926.
62. Polson, A. G., Bass, B. L., and Casey, J. L. (1996) RNA editing of hepatitis delta virus antigenome by dsRNA-adenosine deaminase. *Nature* **380**, 454–456.
63. Egebjerg, J., Kukekov, V., and Heinemann, S. F. (1994) Intron sequence directs RNA editing of the glutamate receptor subunit GluR2 coding sequence. *Proc Natl Acad Sci USA* **91**, 10270–10274.
64. Herb, A., Higuchi, M., Sprengel, R., and Seeburg, P. H. (1996) Q/R site editing in kainate receptor GluR5 and GluR6 pre-mRNAs requires distant intronic sequences. *Proc Natl Acad Sci USA* **93**, 1875–1880.
65. Athanasiadis, A., Rich, A., and Maas, S. (2004) Widespread A-to-I RNA editing of Alu-containing mRNAs in the human transcriptome. *PLoS Biol* **2**, e391.
66. Keegan, L. P., Leroy, A., Sproul, D., and O'Connell, M. A. (2004) Adenosine deaminases acting on RNA (ADARs): RNA-editing enzymes. *Genome Biol* **5**, 209.
67. Valente, L., and Nishikura, K. (2005) ADAR gene family and A-to-I RNA editing: diverse roles in posttranscriptional gene regulation. *Prog Nucleic Acid Res Mol Biol* **79**, 299–338.
68. Chen, C. X., Cho, D. S., Wang, Q., Lai, F., Carter, K. C., and Nishikura, K. (2000) A third member of the RNA-specific adenosine deaminase gene family, ADAR3, contains both single- and double-stranded RNA binding domains. *RNA* **6**, 755–767.
69. Maas, S., Melcher, T., Herb, A., Seeburg, P. H., Keller, W., Krause, S., Higuchi, M., and O'Connell, M. A. (1996) Structural requirements for RNA editing in glutamate receptor pre-mRNAs by recombinant double-stranded RNA adenosine deaminase. *J Biol Chem* **271**, 12221–12226.
70. Cho, D. S., Yang, W., Lee, J. T., Shiekhattar, R., Murray, J. M., and Nishikura, K. (2003) Requirement of dimerization for RNA editing activity of adenosine deaminases acting on RNA. *J Biol Chem* **278**, 17093–17102.
71. Chilibeck, K. A., Wu, T., Liang, C., Schellenberg, M. J., Gesner, E. M., Lynch, J. M., and MacMillan, A. M. (2006) FRET analysis of in vivo dimerization by RNA-editing enzymes. *J Biol Chem* **281**, 16530–16535.

72. Gallo, A., Keegan, L. P., Ring, G. M., and O'Connell, M. A. (2003) An ADAR that edits transcripts encoding ion channel subunits functions as a dimmer. *EMBO J* **22**, 3421–3430.
73. Valente, L., and Nishikura, K. (2007) RNA binding-independent dimerization of adenosine deaminases acting on RNA and dominant negative effects of nonfunctional subunits on dimer functions. *J Biol Chem* **282**, 16054–16061.
74. Macbeth, M. R., Schubert, H. L., Vandemark, A. P., Lingam, A. T., Hill, C. P., and Bass, B. L. (2005) Inositol hexakisphosphate is bound in the ADAR2 core and required for RNA editing. *Science* **309**, 1534–1539.
75. Sato, S., Wong, S. K., and Lazinski, D. W. (2001) Hepatitis delta virus minimal substrates competent for editing by ADAR1 and ADAR2. *J Virol* **75**, 8547–8555.
76. O'Connell, M. A., Gerber, A., and Keller, W. (1997) Purification of human double-stranded RNA-specific editase 1 (hRED1) involved in editing of brain glutamate receptor B pre-mRNA. *J Biol Chem* **272**, 473–478.
77. Polson, A. G., and Bass, B. L. (1994) Preferential selection of adenosines for modification by double-stranded RNA adenosine deaminase. *EMBO J* **13**, 5701–5711.
78. Lehmann, K. A., and Bass, B. L. (1999) The importance of internal loops within RNA substrates of ADAR1. *J Mol Biol* **291**, 1–13.
79. Stefl, R., and Allain, F. H. (2005) A novel RNA pentaloop fold involved in targeting ADAR2. *RNA* **11**, 592–597.
80. Stefl, R., Xu, M., Skrisovska, L., Emeson, R. B., and Allain, F. H. (2006) Structure and specific RNA binding of ADAR2 double-stranded RNA binding motifs. *Structure* **14**, 345–355.
81. Tonkin, L. A., Saccomanno, L., Morse, D. P., Brodigan, T., Krause, M., and Bass, B. L. (2002) RNA editing by ADARs is important for normal behavior in *Caenorhabditis elegans*. *EMBO J* **21**, 6025–6035.
82. Liu, Y., George, C. X., Patterson, J. B., and Samuel, C. E. (1997) Functionally distinct double-stranded RNA-binding domains associated with alternative splice site variants of the interferon-inducible double-stranded RNA-specific adenosine deaminase. *J Biol Chem* **272**, 4419–4428.
83. Lai, F., Chen, C. X., Carter, K. C., and Nishikura, K. (1997) Editing of glutamate receptor B subunit ion channel RNAs by four alternatively spliced DRADA2 double-stranded RNA adenosine deaminases. *Mol Cell Biol* **17**, 2413–2424.
84. Gerber, A., O'Connell, M. A., and Keller, W. (1997) Two forms of human double-stranded RNA-specific editase 1 (hRED1) generated by the insertion of an Alu cassette. *RNA* **3**, 453–463.
85. Kawakubo, K., and Samuel, C. E. (2000) Human RNA-specific adenosine deaminase (ADAR1) gene specifies transcripts that initiate from a constitutively active alternative promoter. *Gene* **258**, 165–172.
86. Rueter, S. M., Dawson, T. R., and Emeson, R. B. (1999) Regulation of alternative splicing by RNA editing. *Nature* **399**, 75–80.
87. Patterson, J. B., and Samuel, C. E. (1995) Expression and regulation by interferon of a double-stranded-RNA-specific adenosine deaminase from human cells: Evidence for two forms of the deaminase. *Mol Cell Biol* **15**, 5376–5388.
88. Herbert, A., Alfken, J., Kim, Y. G., Mian, I. S., Nishikura, K., and Rich, A. (1997) A Z-DNA binding domain present in the human editing enzyme, double-stranded RNA adenosine deaminase. *Proc Natl Acad Sci USA* **94**, 8421–8426.
89. Poulsen, H., Nilsson, J., Damgaard, C. K., Egebjerg, J., and Kjems, J. (2001) CRM1 mediates the export of ADAR1 through a nuclear export signal within the Z-DNA binding domain. *Mol Cell Biol* **21**, 7862–7871.
90. Desterro, J. M., Keegan, L. P., Lafarga, M., Berciano, M. T., O'Connell, M., and Carmo-Fonseca, M. (2003) Dynamic association of RNA-editing enzymes with the nucleolus. *J Cell Sci* **116**, 1805–1818.
91. Sansam, C. L., Wells, K. S., and Emeson, R. B. (2003) Modulation of RNA editing by functional nucleolar sequestration of ADAR2. *Proc Natl Acad Sci USA* **100**, 14018–14023.
92. Paul, M. S., and Bass, B. L. (1998) Inosine exists in mRNA at tissue-specific levels and is most abundant in brain mRNA. *EMBO J* **17**, 1120–1127.
93. Morse, D. P., and Bass, B. L. (1997) Detection of inosine in messenger RNA by inosine-specific cleavage. *Biochemistry* **36**, 8429–8434.
94. Morse, D. P., and Bass, B. L. (1999) Long RNA hairpins that contain inosine are present in *Caenorhabditis elegans* poly(A)⁺ RNA. *Proc Natl Acad Sci USA* **96**, 6048–6053.

95. Morse, D. P., Aruscavage, P. J., and Bass, B. L. (2002) RNA hairpins in noncoding regions of human brain and *Caenorhabditis elegans* mRNA are edited by adenosine deaminases that act on RNA. *Proc Natl Acad Sci USA* **99**, 7906–7911.
96. Blow, M., Futreal, P. A., Wooster, R., and Stratton, M. R. (2004) A survey of RNA editing in human brain. *Genome Res* **14**, 2379–2387.
97. Kim, D. D., Kim, T. T., Walsh, T., Kobayashi, Y., Matisse, T. C., Buyske, S., and Gabriel, A. (2004) Widespread RNA editing of embedded alu elements in the human transcriptome. *Genome Res* **14**, 1719–1725.
98. Levanon, E. Y., Eisenberg, E., Yelin, R., Nemzer, S., Hallegger, M., Shemesh, R., Fligelman, Z. Y., Shoshan, A., Pollock, S. R., Sztybel, D. *et al.* (2004) Systematic identification of abundant A-to-I editing sites in the human transcriptome. *Nat Biotechnol* **22**, 1001–1005.
99. Batzer, M. A., and Deininger, P. L. (2002) Alu repeats and human genomic diversity. *Nat Rev Genet* **3**, 370–379.
100. Neeman, Y., Levanon, E. Y., Jantsch, M. F., and Eisenberg, E. (2006) RNA editing level in the mouse is determined by the genomic repeat repertoire. *RNA* **12**, 1802–1809.
101. Prasanth, K. V., Prasanth, S. G., Xuan, Z., Hearn, S., Freier, S. M., Bennett, C. F., Zhang, M. Q., and Spector, D. L. (2005) Regulating gene expression through RNA nuclear retention. *Cell* **123**, 249–263.
102. Ohlson, J., Enstero, M., Sjoberg, B. M., and Ohman, M. (2005) A method to find tissue-specific novel sites of selective adenosine deamination. *Nucleic Acids Res* **33**, e167.
103. Ohlson, J., Pedersen, J. S., Haussler, D., and Ohman, M. (2007) Editing modifies the GABA(A) receptor subunit alpha3. *RNA* **13**, 698–703.
104. Xia, S., Yang, J., Su, Y., Qian, J., Ma, E., and Haddad, G. G. (2005) Identification of new targets of *Drosophila* pre-mRNA adenosine deaminase. *Physiol Genomics* **20**, 195–202.
105. Nishikura, K. (2006) Editor meets silencer: Crosstalk between RNA editing and RNA interference. *Nat Rev Mol Cell Biol* **7**, 919–931.
106. Wang, Q., Zhang, Z., Blackwell, K., and Carmichael, G. G. (2005) Vigilins bind to promiscuously A-to-I-edited RNAs and are involved in the formation of heterochromatin. *Curr Biol* **15**, 384–391.
107. Luciano, D. J., Mirsky, H., Vendetti, N. J., and Maas, S. (2004) RNA editing of a miRNA precursor. *RNA* **10**, 1174–1177.
108. Pfeffer, S., Sewer, A., Lagos-Quintana, M., Sheridan, R., Sander, C., Grasser, F. A., van Dyk, L. F., Ho, C. K., Shuman, S., Chien, M., *et al.* (2005) Identification of microRNAs of the herpesvirus family. *Nat Methods* **2**, 269–276.
109. Blow, M. J., Grocock, R. J., van Dongen, S., Enright, A. J., Dicks, E., Futreal, P. A., Wooster, R., and Stratton, M. R. (2006) RNA editing of human microRNAs. *Genome Biol* **7**, R27.
110. Yang, W., Chendrimada, T. P., Wang, Q., Higuchi, M., Seeburg, P. H., Shiekhattar, R., and Nishikura, K. (2006) Modulation of microRNA processing and expression through RNA editing by ADAR deaminases. *Nat Struct Mol Biol* **13**, 13–21.
111. Bushati, N., and Cohen, S. M. (2007) microRNA Functions. *Annu Rev Cell Dev Biol* **23**, 175–205.
112. Kawahara, Y., Zinshteyn, B., Sethupathy, P., Iizasa, H., Hatzigeorgiou, A. G., and Nishikura, K. (2007) Redirection of silencing targets by adenosine-to-inosine editing of miRNAs. *Science* **315**, 1137–1140.
113. Reenan, R. A. (2005) Molecular determinants and guided evolution of species-specific RNA editing. *Nature* **434**, 409–413.
114. Rosenthal, J. J., and Bezanilla, F. (2002) Extensive editing of mRNAs for the squid delayed rectifier K⁺ channel regulates subunit tetramerization. *Neuron* **34**, 743–757.
115. Patton, D. E., Silva, T., and Bezanilla, F. (1997) RNA editing generates a diverse array of transcripts encoding squid Kv2 K⁺ channels with altered functional properties. *Neuron* **19**, 711–722.
116. Saccomanno, L., and Bass, B. L. (1999) A minor fraction of basic fibroblast growth factor mRNA is deaminated in *Xenopus* stage VI and matured oocytes. *RNA* **5**, 39–48.
117. Keegan, L. P., Brindle, J., Gallo, A., Leroy, A., Reenan, R. A., and O'Connell, M. A. (2005) Tuning of RNA editing by ADAR is required in *Drosophila*. *EMBO J* **24**, 2183–2193.
118. Hanrahan, C. J., Palladino, M. J., Ganetzky, B., and Reenan, R. A. (2000) RNA editing of the *Drosophila* para Na⁽⁺⁾ channel transcript. Evolutionary conservation and developmental regulation. *Genetics* **155**, 1149–1160.
119. Semenov, E. P., and Pak, W. L. (1999) Diversification of *Drosophila* chloride channel gene by multiple posttranscriptional mRNA modifications. *J Neurochem* **72**, 66–72.

120. Peixoto, A. A., Smith, L. A., and Hall, J. C. (1997) Genomic organization and evolution of alternative exons in a *Drosophila* calcium channel gene. *Genetics* **145**, 1003–1013.
121. Petschek, J. P., Scheckelhoff, M. R., Mermer, M. J., and Vaughn, J. C. (1997) RNA editing and alternative splicing generate mRNA transcript diversity from the *Drosophila* 4f-rnp locus. *Gene* **204**, 267–276.
122. Grauso, M., Reenan, R. A., Culetto, E., and Sattelle, D. B. (2002) Novel putative nicotinic acetylcholine receptor subunit genes, Dalpha5, Dalpha6 and Dalpha7, in *Drosophila melanogaster* identify a new and highly conserved target of adenosine deaminase acting on RNA-mediated A-to-I pre-mRNA editing. *Genetics* **160**, 1519–1533.
123. Jones, A. K., Raymond-Delpech, V., Thany, S. H., Gauthier, M., and Sattelle, D. B. (2006) The nicotinic acetylcholine receptor gene family of the honey bee. *Apis mellifera*. *Genome Res* **16**, 1422–1430.
124. Diegelmann, S., Nieratschker, V., Werner, U., Hoppe, J., Zars, T., and Buchner, E. (2006) The conserved protein kinase-A target motif in synapsin of *Drosophila* is effectively modified by pre-mRNA editing. *BMC Neurosci* **7**, 76.
125. Gao, J. R., Deacutis, J. M., and Scott, J. G. (2007) The nicotinic acetylcholine receptor subunit Mdelta6 from *Musca domestica* is diversified via post-transcriptional modification. *Insect Mol Biol* **16**, 325–334.